Rahul Singhvi, ScD, MBA Takeda Vaccines

Rahul Singhvi is Chief Operating Officer of Takeda’s Global Vaccine Business Unit and is responsible for global supply of vaccines at the Takeda Pharmaceutical Company.

Before joining Takeda, Dr. Singhvi was President and CEO of Novavax, Inc. a Nasdaq-listed biotechnology company (NVAX). During his tenure at Novavax, Dr. Singhvi transformed the company from a specialty pharmaceutical business to a premier vaccine company and increased its valuation from $30M to over $300M over his tenure as CEO.  Dr. Singhvi’s professional career began at Merck & Co in 1994, where he held several positions in R&D and manufacturing.  At Merck, he co-lead a project team that oversaw the development of Varivax®III (chickenpox vaccine), ProQuad® (MMRV pediatric combination vaccine) and Zostavax® (Shingles vaccine).

Dr. Singhvi graduated as the top ranked chemical engineer from IIT, Kanpur, India and obtained both his MS and ScD chemical engineering degrees from MIT. He received an MBA degree from the Wharton School of the University of Pennsylvania, where he graduated as a Palmer Scholar.